Cargando…
ATRT-07. CLINICAL APPLICABILITY OF C19MC MIRNA DETECTION IN LIQUID BIOPSIES OF ETMR PATIENTS
Embryonal tumor with multilayered rosettes (ETMR) is a distinct central nervous system tumor entity which is characterized by dysregulation of oncogenic micro RNAs (miRNA). In the majority of cases (approx. 90%), tumors are characterized by amplification of the C19MC locus accompanied by a fusion of...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10260048/ http://dx.doi.org/10.1093/neuonc/noad073.007 |
_version_ | 1785057776473473024 |
---|---|
author | Madlener, Sibylle Furtner, Julia Stepien, Natalia Senfter, Daniel Mayr, Lisa Zeyda, Maximilian Gramss, Leon Aistleitner, Barbara Spiegl-Kreinecker, Sabine Rivelles, Elisa Dorfer, Christian Rössler, Karl Czech, Thomas Azizi, Amedeo A Peyrl, Andreas Lötsch-Gojo, Daniela Müllauer, Leonhard Haberler, Christine Slavc, Irene Gojo, Johannes |
author_facet | Madlener, Sibylle Furtner, Julia Stepien, Natalia Senfter, Daniel Mayr, Lisa Zeyda, Maximilian Gramss, Leon Aistleitner, Barbara Spiegl-Kreinecker, Sabine Rivelles, Elisa Dorfer, Christian Rössler, Karl Czech, Thomas Azizi, Amedeo A Peyrl, Andreas Lötsch-Gojo, Daniela Müllauer, Leonhard Haberler, Christine Slavc, Irene Gojo, Johannes |
author_sort | Madlener, Sibylle |
collection | PubMed |
description | Embryonal tumor with multilayered rosettes (ETMR) is a distinct central nervous system tumor entity which is characterized by dysregulation of oncogenic micro RNAs (miRNA). In the majority of cases (approx. 90%), tumors are characterized by amplification of the C19MC locus accompanied by a fusion of this locus to the TTYH1 gene. Beside the very young age of the patients, ETMR is a highly aggressive brain tumor with a dismal clinical outcome. About half of the patients relapse within the first 6 months despite intensive therapy. Based on these facts, a more rapid diagnosis as well as more accurate and faster detection of tumor response or tumor relapse would significantly improve the management of these severely affected young patients. Liquid biopsy has emerged as a highly promising tool to enable minimal invasive detection of molecular parameters to facilitate diagnosis and patient monitoring. Here, we developed a miRNA based liquid biopsy tool and performed a comprehensive profiling of the miRNA landscape in 11 ETMR tumor tissues and matching liquid biopsy samples of patients. The screening of the initial liquid biopsy samples (plasma or serum) taken at diagnosis revealed distinctly enriched miRNA levels. Further, we evaluated the use of the miRNA levels as a longitudinal tumor-monitoring tool. We detected decreasing levels after tumor resection and in long-term survivors and vice versa increasing levels in patients with progressive tumor disease. In conclusion, we developed a reliable and fast method with a turnaround time of only 4 hours between blood draw and analysis of the aberrant expressed miRNA in liquid biopsy samples of ETMR patients correlating with the clinical course of the individual patient. |
format | Online Article Text |
id | pubmed-10260048 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-102600482023-06-13 ATRT-07. CLINICAL APPLICABILITY OF C19MC MIRNA DETECTION IN LIQUID BIOPSIES OF ETMR PATIENTS Madlener, Sibylle Furtner, Julia Stepien, Natalia Senfter, Daniel Mayr, Lisa Zeyda, Maximilian Gramss, Leon Aistleitner, Barbara Spiegl-Kreinecker, Sabine Rivelles, Elisa Dorfer, Christian Rössler, Karl Czech, Thomas Azizi, Amedeo A Peyrl, Andreas Lötsch-Gojo, Daniela Müllauer, Leonhard Haberler, Christine Slavc, Irene Gojo, Johannes Neuro Oncol Final Category: ATRT/Embryonal/ETMR - ATRT Embryonal tumor with multilayered rosettes (ETMR) is a distinct central nervous system tumor entity which is characterized by dysregulation of oncogenic micro RNAs (miRNA). In the majority of cases (approx. 90%), tumors are characterized by amplification of the C19MC locus accompanied by a fusion of this locus to the TTYH1 gene. Beside the very young age of the patients, ETMR is a highly aggressive brain tumor with a dismal clinical outcome. About half of the patients relapse within the first 6 months despite intensive therapy. Based on these facts, a more rapid diagnosis as well as more accurate and faster detection of tumor response or tumor relapse would significantly improve the management of these severely affected young patients. Liquid biopsy has emerged as a highly promising tool to enable minimal invasive detection of molecular parameters to facilitate diagnosis and patient monitoring. Here, we developed a miRNA based liquid biopsy tool and performed a comprehensive profiling of the miRNA landscape in 11 ETMR tumor tissues and matching liquid biopsy samples of patients. The screening of the initial liquid biopsy samples (plasma or serum) taken at diagnosis revealed distinctly enriched miRNA levels. Further, we evaluated the use of the miRNA levels as a longitudinal tumor-monitoring tool. We detected decreasing levels after tumor resection and in long-term survivors and vice versa increasing levels in patients with progressive tumor disease. In conclusion, we developed a reliable and fast method with a turnaround time of only 4 hours between blood draw and analysis of the aberrant expressed miRNA in liquid biopsy samples of ETMR patients correlating with the clinical course of the individual patient. Oxford University Press 2023-06-12 /pmc/articles/PMC10260048/ http://dx.doi.org/10.1093/neuonc/noad073.007 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Final Category: ATRT/Embryonal/ETMR - ATRT Madlener, Sibylle Furtner, Julia Stepien, Natalia Senfter, Daniel Mayr, Lisa Zeyda, Maximilian Gramss, Leon Aistleitner, Barbara Spiegl-Kreinecker, Sabine Rivelles, Elisa Dorfer, Christian Rössler, Karl Czech, Thomas Azizi, Amedeo A Peyrl, Andreas Lötsch-Gojo, Daniela Müllauer, Leonhard Haberler, Christine Slavc, Irene Gojo, Johannes ATRT-07. CLINICAL APPLICABILITY OF C19MC MIRNA DETECTION IN LIQUID BIOPSIES OF ETMR PATIENTS |
title | ATRT-07. CLINICAL APPLICABILITY OF C19MC MIRNA DETECTION IN LIQUID BIOPSIES OF ETMR PATIENTS |
title_full | ATRT-07. CLINICAL APPLICABILITY OF C19MC MIRNA DETECTION IN LIQUID BIOPSIES OF ETMR PATIENTS |
title_fullStr | ATRT-07. CLINICAL APPLICABILITY OF C19MC MIRNA DETECTION IN LIQUID BIOPSIES OF ETMR PATIENTS |
title_full_unstemmed | ATRT-07. CLINICAL APPLICABILITY OF C19MC MIRNA DETECTION IN LIQUID BIOPSIES OF ETMR PATIENTS |
title_short | ATRT-07. CLINICAL APPLICABILITY OF C19MC MIRNA DETECTION IN LIQUID BIOPSIES OF ETMR PATIENTS |
title_sort | atrt-07. clinical applicability of c19mc mirna detection in liquid biopsies of etmr patients |
topic | Final Category: ATRT/Embryonal/ETMR - ATRT |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10260048/ http://dx.doi.org/10.1093/neuonc/noad073.007 |
work_keys_str_mv | AT madlenersibylle atrt07clinicalapplicabilityofc19mcmirnadetectioninliquidbiopsiesofetmrpatients AT furtnerjulia atrt07clinicalapplicabilityofc19mcmirnadetectioninliquidbiopsiesofetmrpatients AT stepiennatalia atrt07clinicalapplicabilityofc19mcmirnadetectioninliquidbiopsiesofetmrpatients AT senfterdaniel atrt07clinicalapplicabilityofc19mcmirnadetectioninliquidbiopsiesofetmrpatients AT mayrlisa atrt07clinicalapplicabilityofc19mcmirnadetectioninliquidbiopsiesofetmrpatients AT zeydamaximilian atrt07clinicalapplicabilityofc19mcmirnadetectioninliquidbiopsiesofetmrpatients AT gramssleon atrt07clinicalapplicabilityofc19mcmirnadetectioninliquidbiopsiesofetmrpatients AT aistleitnerbarbara atrt07clinicalapplicabilityofc19mcmirnadetectioninliquidbiopsiesofetmrpatients AT spieglkreineckersabine atrt07clinicalapplicabilityofc19mcmirnadetectioninliquidbiopsiesofetmrpatients AT rivelleselisa atrt07clinicalapplicabilityofc19mcmirnadetectioninliquidbiopsiesofetmrpatients AT dorferchristian atrt07clinicalapplicabilityofc19mcmirnadetectioninliquidbiopsiesofetmrpatients AT rosslerkarl atrt07clinicalapplicabilityofc19mcmirnadetectioninliquidbiopsiesofetmrpatients AT czechthomas atrt07clinicalapplicabilityofc19mcmirnadetectioninliquidbiopsiesofetmrpatients AT aziziamedeoa atrt07clinicalapplicabilityofc19mcmirnadetectioninliquidbiopsiesofetmrpatients AT peyrlandreas atrt07clinicalapplicabilityofc19mcmirnadetectioninliquidbiopsiesofetmrpatients AT lotschgojodaniela atrt07clinicalapplicabilityofc19mcmirnadetectioninliquidbiopsiesofetmrpatients AT mullauerleonhard atrt07clinicalapplicabilityofc19mcmirnadetectioninliquidbiopsiesofetmrpatients AT haberlerchristine atrt07clinicalapplicabilityofc19mcmirnadetectioninliquidbiopsiesofetmrpatients AT slavcirene atrt07clinicalapplicabilityofc19mcmirnadetectioninliquidbiopsiesofetmrpatients AT gojojohannes atrt07clinicalapplicabilityofc19mcmirnadetectioninliquidbiopsiesofetmrpatients |